Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04682587
Other study ID # A4061097
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 24, 2021
Est. completion date April 5, 2021

Study information

Verified date September 2022
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To assess how dose reductions or treatment interruptions related to axitinib can be implemented to manage and resolve adverse events occurring among patients with advanced renal cell carcinoma treated with first-line axitinib in combination with avelumab or pembrolizumab


Description:

The specific objectives of the study are as follows: Describe incident adverse events (AEs) experienced among patients with advanced RCC who received first-line axitinib in combination with immuno-oncology (IO) therapies. - Type and seriousness of AEs (ie, diarrhea, fatigue, hypertension, nausea, palmar plantar erythrodysesthesia [hand-foot syndrome]). - Proportion of patients who experienced repeated AEs. - Time from treatment initiation to AE onset, overall and by type and seriousness of AEs. Among patients with advanced RCC who developed incident AEs while receiving first line axitinib in combination with IO therapies, characterize and describe management strategies for AEs, stratified by type and seriousness of AEs. - Proportion of patients who used each of the following management strategies: - No action for axitinib and IO therapy; - No action for axitinib, but treatment modification for IO therapy (ie, treatment interruption, treatment discontinuation); - Axitinib dose reduction, but no action for IO therapy; - Axitinib treatment interruption, but no action for IO therapy; - Axitinib treatment discontinuation, but no action for IO therapy; - Axitinib dose reduction, and treatment modification for IO therapy; - Axitinib treatment interruption, and treatment modification for IO therapy; - Axitinib treatment discontinuation, and treatment modification for IO therapy. - Average axitinib dose reduction (absolute and percentage change), where applicable. - Duration of treatment interruption, where applicable. Assess the frequency of and time to AE resolution (from AE onset and initiation of management strategy, separately) among patients with advanced RCC who developed incident AEs while receiving first-line axitinib in combination with IO therapies according to different management strategies implemented, stratified further by type and seriousness of AEs, as allowed by sample size. The above objectives will also be conducted for repeated AEs of the same type


Recruitment information / eligibility

Status Completed
Enrollment 481
Est. completion date April 5, 2021
Est. primary completion date April 5, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Physicians meeting the following criteria will be invited to participate in the chart review study: - Specialty in oncology - Access to complete medical records for at least one patient with advanced RCC who meets the patient eligibility criteria Eligible oncologists will be asked to select up to three patients meeting the following criteria for inclusion in the chart review study: - Confirmed diagnosis with advanced RCC - Treated with first-line axitinib/IO combination therapy at or after diagnosis - Experienced at least one AE (i.e., diarrhea, fatigue, nausea, hypertension, and palmar-plantar erythrodysesthesia [hand-foot syndrome]) while treated with axitinib/IO combination therapy - Age 18 years or older at the time of advanced RCC diagnosis - Initiated axitinib/IO combination therapy at least 3 months prior to the start date of medical chart abstraction to ensure sufficient follow-up time Exclusion Criteria: There are no exclusion criteria for this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Axitinib
Inlyta, axitinib
Avelumab
Avelumab, Bavencio
Pembrolizumab
Pembrolizumab, Keytruda

Locations

Country Name City State
United States Pfizer New York New York

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Describe incident Adverse Events (AEs) experienced among patients with advanced RCC who received first-line axitinib in combination with immune-oncology IO therapies Descriptive analyses of incident AEs During the intervention
Primary Characterize and describe management strategies for AEs , stratified by type and seriousness of AEs Descriptive analyses of management strategies to resolve AEs During the intervention
Primary Assess the frequency of and time to AE resolution (from AE onset and initiation of management strategy, separately) Time to AEs resolution During axitinib treatment period
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04987203 - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Phase 3
Recruiting NCT06391879 - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Completed NCT02853344 - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Phase 2
Terminated NCT04088500 - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma Phase 2
Completed NCT05070637 - Circulating Tumor Cell Reducing No-touch Nephrectomy N/A
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Not yet recruiting NCT06049030 - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT01358721 - Phase I Biomarker Study (BMS-936558) Phase 1
Active, not recruiting NCT04503148 - Anesthesia and Cancer Study: Renal Cell Carcinoma N/A
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Not yet recruiting NCT05808608 - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma Phase 1/Phase 2
Withdrawn NCT03323710 - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma Phase 2
Completed NCT03052504 - Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy